The ruling blocks Lupin and Zydus Life from selling their generic version of Mirabegron, the bioequivalent of Astellas' ...

to market a generic equivalent of Descovy® Tablets, 200 mg/25 mg of Gilead Sciences, Inc," Lupin said in an exchange filing. The approval allows Lupin to market a generic version of Descovy ...

The ruling would be viewed as a negative development for Lupin and Zydus, as it effectively blocks their ability to market ...

Global pharma major Lupin Limited (Lupin) announced that it has launched rivaroxaban tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the US FDA.